口腔幽门螺杆菌感染与胃幽门螺杆菌感染及根除率的相关性

目的:探讨口腔幽门螺杆菌(Helicobacter pylori,H.pylori)感染与胃H.pylori感染及根除率的相关性.方法:对150例患者采用~(14)C-尿素呼气试验(~(14)C-urea breath test,~(14)C-UBT)、胃黏膜组织学检查(改良Giemsa染色)及细菌培养联合检测来判断胃内H.pylori感染情况,用H.pylori唾液测试板(HPS法)判断口腔H.pylori感染情况.选取胃与口腔H.pylori均阳性患者81例,随机分组后分别予以方案A(常规四联药物)或方案B[常规四联药物+多聚赖氨酸复合体漱口液(迪倍思)清洁口腔]治疗,胃H.pylori阳性、口腔H.pylori阴性患者27例则全部予方案A治疗,治疗结束后4、12 wk复查~(14)C-UBT及HPS观察胃及口腔H.pylori感染及根除情况.结果:150例患者中,胃H.pylori阳性患者口腔H.pylori阳性率75.00%(81/108)高于胃H.pylori阴性患者口腔H.pylori阳性率38.10%(16/42),差异有统计学意义(X~2=18.025,P0.05),治疗后4wk方案A胃H.pylori根除率:口腔H.pylori阳性组为60.98%(25/41),低于口腔H.pylori阴性组88.89%(24/27),两组比较有统计学差异(X~2=6.300,P0.05);方案B治疗胃H.pylori根除率90.00%(36/40),口腔H.pylori根除率65.00%(26/40),均高于方案A治疗组(60.98%、17.07%),比较有统计学差异(X~2=7.168,P0.05),治疗后12 w k各组根除率比较与4 wk结果类似.结论:口腔H.pylori感染与胃H.pylori感染有相关性,并可降低常规药物治疗H.pylori的根除率;口腔与胃的多途径综合治疗方案可显著提高H.pylori感染的根除率.     

肠易激综合征患者胆囊运动功能的研究

目的 了解肠易激综合征患者的胆囊运动功能情况,协助肠易激综合征的治疗。方法 我们通过对健康志愿者(对照组)和肠易激综合征患者(IBS组)用核素显相测定胆囊排空功能。结果 IBS组23例中有13例(56.5％13／23),对照组16例中有4例(25％4／16),餐后1小时胆囊排空指数(GBEF)降低,两组比较差异有显著性(P<0.01)。餐后30、40、50和60minGBEF IBS组均低于对照组,差异有非常显著性(P<0.01)。结论 IBS组胆囊排空率下降,排空功能不良。在治疗肠易激综合征同时予利胆促动力剂治疗。     

益生菌联合四联疗法治疗老年人幽门螺杆菌感染的临床观察

目的探讨益生菌在治疗老年人幽门螺杆菌(H.pylori)感染中的价值。方法入选2014年1月至10月解放军总医院南楼临床部消化内科120例老年H.pylori感染患者,根据年龄性别进行随机区组设计,分为益生菌治疗组和对照组,各60例。对照组给予阿莫西林+克拉霉素+雷贝拉唑+胶体果胶铋标准四联疗法,治疗组给予酪酸梭菌肠球菌三联活菌片+四联疗法,两组疗程均为14 d,治疗结束4周后复查~(13)C尿素呼气试验(~(13)C UBT),观察并比较两组患者H.pylori根除率及不良反应发生情况。结果 117例患者按方案完成治疗。治疗组和对照组按意向治疗(ITT)分析H.pylori根除率分别为83.33%和71.67%,按方案(PP)分析H.pylori根除率分别为86.21%和72.88%,治疗组ITT和PP根除率均明显高于对照组,但差异无统计学意义(P0.05),随访1年后复查,治疗组H.pylori根除率仍显著高于对照组,差异有统计学意义(P0.05);治疗组不良反应发生率为10.34%,明显低于对照组的27.12%,差异有统计学意义(P0.05)。治疗组对药物的耐受程度显著优于对照组(P0.05)。结论益生菌联合标准四联疗法能有效提高H.pylori根除率,并且能显著降低药物不良反应。     

幽门螺杆菌感染与桥本甲状腺炎的前瞻性研究

背景桥本甲状腺炎是最常见的自身免疫性疾病,发病率逐年增高,但其病因及发病机制尚不十分清楚.幽门螺杆菌(Helicobacter pylori, H. pylori)感染与桥本甲状腺炎的关系是当前研究热点,但桥本甲状腺炎患者是否应常规筛查并根除H. pylori尚不清楚.目的探讨H. pylori感染与桥本甲状腺炎的关系,并前瞻性研究桥本甲状腺炎患者根除H. pylori是否获益.为桥本甲状腺炎患者早期是否应积极筛查并根除H.pylori提供参考.方法随机纳入2018-01/2018-12我院甲状腺工程技术诊疗中心首次就诊的甲功正常的桥本甲状腺炎患者300例,另选取体检中心300例与之匹配的健康人群作为对照组.用化学发光法对两组进行甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)及甲状腺功能的测定.碳13尿素呼气试验检测H. pylori感染.(1)比较H.pylori感染和未感染者桥本甲状腺炎的患病率;(2)桥本甲状腺炎组,比较H. pylori阳性和阴性者TPOAb和TGAb的滴度;(3)将H. pylori阳性的桥本甲状腺炎患者随机分为治疗组和对照组,治疗组予抗H. pylori治疗,对照组不予治疗.治疗结束1 mo后复查碳13尿素呼气试验评估根除治疗是否成功.在完成治疗后6 mo、12 mo,再测定两组TPOAb和TGAb滴度并与治疗前比较.结果H.pylori阳性组桥本甲状腺炎患病率64.67%(194/300),H.pylori阴性组桥本甲状腺炎患病率35.33%(106/300),差异有统计学意义(P0.05);桥本甲状腺炎患者中, H.pylori感染者TPOAb和TGAb显著高于H.pylori阴性者.治疗组根除H. pylori后,其TPOAb和TGAb的滴度较治疗前明显下降(P0.05),而对照组变化不大.结论H. pylori感染者桥本甲状腺炎患病率升高. H. pylori感染可使桥本甲状腺炎患者TPOAb和TGAb滴度升高.根除H. pylori可显著降低桥本甲状腺炎患者TPOAb和TGAb滴度.桥本甲状腺炎患者建议早期常规筛查H. pylori感染并积极根除.     

胃黏膜癌前病变中p53、p21^ras蛋白表达与幽门螺杆菌感染的关系

目的观察幽门螺杆菌(Helicobacterpylori)感染及根除H.pylori二年后p53、p21ras在二组胃黏膜上皮细胞的表达,探讨H.pylori在胃癌发生、发展中的作用.方法应用免疫组织化学染色、尿素酶快速试验(RUT)、组织学Warthin-Starry染色.198例H.pylori感染患者,慢性胃炎86例,慢性胃炎伴肠化生67例,慢性胃炎伴异型增生45例;对照组为根除H.pylori 2年后共86例,其中慢性胃炎54例,慢性胃炎伴肠化生32例,慢性胃炎伴异型增生10例.全部病例做p53、p21ras免疫组织化学染色.结果 H.pylori感染组p53、p21 ras 阳性表达率15.7%、18.7%,明显高于H.pylori根除组2.3%、7%,差异显著(P＜0.05);慢性胃炎伴肠化病变中,p53、p21ras在H.pylori感染组阳性表达率17.9%、18.4%均高于H.pylori根除组0%、9.4%,差异显著(P＜0.05)慢性胃炎伴异型增生病变中,p53、p21 ras在H.pylori感染组阳性表达率31.1%、40%均高于H.pylori根除组20%、30.4%,差异显著(P＜0.05);H.pylori 感染组p53、p21ras在慢性胃炎,肠化生,异型增生表达水平依次增高p53、p21ras共同表达阳性37例.结论在胃黏膜癌前病变中p53、p21ras 在H.pylori感染组阳性表达率高于H.pylori根除组,差异显著(P＜0.05);在慢性胃炎,肠化生,异型增生p53、p21ras表达水平在增高;p53、p21 ras表达呈正相关;H.pylori感染在胃癌发生、发展过程中起一定作用,p53、p21ras表达可能是H.pylori致癌的作用机理之一.     

消化不良妊娠妇女中幽门螺杆菌的表达研究

目的探究功能性消化不良妊娠妇女中幽门螺杆菌(H.pylori)的表达,并分析功能性消化不良与H.pylori感染的关系,为临床治疗妊娠期消化不良提供依据。方法选取湖北省武穴市第三医院妇产科门诊接诊的功能性消化不良妊娠妇女73例作为观察组,并选取同期在湖北省武穴市第三医院妇产科门诊进行产检且无消化不良症状的68例妊娠妇女作为对照组。比较两组血清H.pylori抗体(H.pyloriIg G)阳性率、13C-尿素呼气试验(13C-UBT)结果及细胞毒素相关基因A的情况,并进行分析。结果观察组血清H.pylori-Ig G阳性率(71.2%)略高于对照组(61.8%),两组间差异不明显(P0.05)。观察组13C-UBT检测阳性率(79.5%)略高于对照组(66.2%),两组间差异不明显(P0.05)。在检查出H.pylori阳性的病例中,观察组中Cag A的阳性率为61.5%,明显高于对照组的40.5%,两组差异有统计学意义(P0.05)。结论妊娠妇女的消化不良症状与高致病性的H.pylori菌株有密切关系,临床治疗应将根除H.pylori作为治疗基础。     

感染后肠易激综合征患者肠黏膜炎性细胞因子的失衡

目的通过检测感染后肠易激综合征(pIBS)患者肠黏膜炎性细胞因子白细胞介素(IL)-6、IL-18和IL-13的表达,探讨Th1及Th2淋巴细胞在感染后肠易激综合征发病中的作用和机制。方法随机抽取肠易激综合征(IBS)患者50例,其中感染后肠易激综合征患者23例,非感染后肠易激综合征(non-pIBS)患者27例,另设结肠息肉电切术后复查者20例为对照组,应用免疫组化方法分别检测肠易激综合征患者和对照组回盲部、直肠黏膜IL-6、IL-18、IL-13的表达。结果感染后IBS患者IL-6、IL-18的黏膜表达阳性率高于对照组(P0.05)及非感染后IBS组(P0.05);非感染后IBS患者IL-6、IL-18的黏膜表达阳性率与对照组比较无显著差异(P0.05);IL-13在感染后IBS及非感染后IBS患者回盲部及直肠的阳性表达率与对照组比较无明显差异(P0.05)。结论感染后肠易激综合征患者以Th1反应为主,促炎细胞因子可能诱发Th1/Th2的平衡失调。     

幽门螺杆菌阳性消化性溃疡的治疗及护理效果

目的:探讨幽门螺杆菌(Helicobacter pylori,H.pylori)阳性消化性溃疡采用四联疗法治疗及给予综合系统护理的临床疗效.方法:收集余姚市第二人民医院2012-03/2013-10收治的198例H.pylori阳性消化性溃疡患者,随机分为两组,观察组99例,对照组99例,观察组采用对枸橼酸铋钾+阿莫西林+克拉霉素+埃索美拉唑四联治疗及给予综合系统护理,疗程为2 wk,对照组采取阿莫西林+克拉霉素+埃索美拉唑三联治疗及一般常规护理,治疗结束复查胃镜,观察两组患者治疗及护理效果.结果:观察组治疗痊愈28例(28.3%),显效60例(60.1%),有效5例(5.1%),无效6例(6.1%),总有效率93.9%,对照组治疗后痊愈16例(16.2%),显效42例(42.4%),有效15例(15.1%),无效26例(26.3%),总有效率73.4%,治疗效果有显著差异(P<0.05);治疗结束后4 wk观察组H.pylori阴性89例,H.pylori根除率为89.9%,对照组H.pylori阴性62例,H.pylori根除率为(62.6%),有显著差异,具有统计学意义(P<0.05).结论:应用四联疗法治疗配合综合系统的护理H.pylori患者,能有效根除H.pylori,对治疗H.pylori阳性消化性溃疡患者有良好的治疗效果,值得临床推广应用.     

幽门螺杆菌感染及其根除治疗对轻微肝性脑病患者的临床价值

目的探讨幽门螺杆菌(H.pylori)感染与轻微肝性脑病(mild hepatic encephalopathy, MHE)的关系,分析根除H.pylori对MHE的临床价值。方法选取我院2018年11月至2020年8月诊断为MHE的患者56例,同期健康体检者40名,将~(13)C呼气检测H.pylori阳性的42例患者随机分为观察组和对照组,各21例。检测两组患者ALT、AST、总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)、血氨水平及NCT、DST评分,同时对观察组患者行H.pylori根除治疗,比较两组治疗前后上述指标水平的变化情况。结果与健康体检者相比,MHE患者更易合并H.pylori感染,差异有统计学意义(χ~2=4.61,P0.05);观察组与对照组H.pylori根除治疗前ALT、AST、TBIL、DBIL、IBIL、血氨水平变化及NCT、DST评分方面差异均无统计学意义(P0.05),根除治疗后较治疗前DST评分值升高,余指标均下降,且对照组明显优于观察组,差异有统计学意义(P0.05)。结论 H.pylori感染与MHE密切相关,H.pylori根除治疗后能够改善患者肝功能,降低血氨水平,缓解患者的临床症状,对治疗MHE具有一定的指导意义。     

幽门螺杆菌根除疗法结合叶酸对慢性萎缩性胃炎患者的远期效果

目的探讨幽门螺杆菌(Helicobacter pylori,H.pylori)根除疗法结合叶酸对慢性萎缩性胃炎(chronic atrophic gastritis,CAG)患者的远期效果.方法选取2013-07/2014-06于永嘉县中医医院门诊的123例行H.pylori根除治疗的CAG患者为研究对象,根据治疗方案分为联合组(n=71)和单纯根除组(n=52),单纯根除组患者给予标准三联H.pylori根除治疗,联合组患者在根除H.pylori成功后口服叶酸片3 mo.在治疗后2年进行胃镜随访,比较2组患者治疗前后可操作的与胃癌风险联系的肠化生评估(operative link for gastric intestinal metaplasia assessment,OLGIM)和萎缩评估(operative link for gastritis assessment,OLGA)分期,根据治疗后2年的13C尿素呼气试验结果将联合组患者分为H.pylori根除成功组(n=49)和H.pylori再感染组(n=22),比较3组治疗前后的CAG病变评分.结果治疗后2年,联合组的OLGIM和OLGA分期明显优于单纯根除组,差异均有统计学意义(P0.05).治疗后2年,H.pylori根除成功组和单纯根除组患者的CAG病变评分显著低于同组治疗前,差异均有统计学意义(P0.05),而H.pylori再感染组治疗前后的CAG病变评分比较,差异无统计学意义(P0.05).组间比较,H.pylori根除成功组的CAG病变评分显著低于H.pylori再感染组和单纯根除组,差异均有统计学意义(P0.05),H.pylori再感染组与单纯根除组治疗后的CAG病变评分比较,差异无统计学意义(P0.05).结论 H.pylori根除治疗联合叶酸能显著改善CAG患者的胃黏膜萎缩和肠化生程度,促进其病情恢复,远期应用效果令人满意,且H.pylori成功根除者的效果更好.     

Is there an association between Helicobacter pylori infection and irritable bowel syndrome? A meta-analysis

BACKGROUND Irritable bowel syndrome(IBS) is a prevalent and debilitating gastrointestinal condition. Research has reported persistent, low-grade mucosal inflammation and significant overlaps between patients with IBS and those with dyspepsia,suggesting a possible pathogenic role of Helicobacter pylori(H. pylori) in IBS. This study therefore aimed to provide the first systematic review and meta-analysis on the association between H. pylori infection and IBS.AIM To investigate the association between H. pylori infection and IBS.METHODS Using the keywords "H. pylori OR Helicobacter OR Helicobacter pylori OR infection" AND "irritable bowel syndrome OR IBS", a preliminary search of PubMed, Medline, Embase, Cochrane Database of Systematic Reviews, Web of Science, Google Scholar and WanFang databases yielded 2924 papers published in English between 1 January 1960 and 1 June 2018. Attempts were also made to search grey literature.RESULTSA total of 13 clinical studies were systematically reviewed and nine studies were included in the final meta-analysis. Random-effects meta-analysis found a slight increased likelihood of H. pylori infection in patients with IBS, albeit this was not statistically significant(pooled odds ratio 1.47, 95% confidence interval: 0.90-2.40,P = 0.123). It must also be acknowledged that all of the available studies reported only crude odd ratios. H. pylori eradication therapy also does not appear to improve IBS symptoms. Although publication bias was not observed in the funnel plot, there was a high degree of heterogeneity amongst the studies included in the meta-analysis(I2 = 87.38%).CONCLUSION Overall, current evidence does not support an association between IBS and H.pylori infection. Further rigorous and detailed studies with larger sample sizes and after H. pylori eradication therapy are warranted.     

H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome

BACKGROUND/AIM: Irritable bowel syndrome (IBS) is characterized by abdominal pain and changes in stool habits. Visceral hypersensitivity (VH) is a key factor in the pathophysiology of IBS. The role of Helicobacter pylori infection in the induction of VH in the upper gastrointestinal tract is controversially discussed. The aim of this study is to evaluate the value of rectal barostat in eliciting abdominal symptoms in patients with IBS in relation to H. pylori infection. PATIENTS AND METHODS: 31 patients (19 female, 12 male, mean age 45.6 +/- 10 years) with normal colonoscopy and clinical signs of IBS were examined by rectal barostat (pressure-controlled balloon distension in the rectum). Induction of typical abdominal discomfort (far from the balloon) defined the examination positive. Level of nonpainful perception (L1), feeling of defecation (L2), and pain or stool urgency (L3) were registered in comparison with a healthy control group (CG; n = 15, 9 female, 6 male). The H. pylori status was defined by (13)C-urea breath test (n = 46). RESULTS: Typical abdominal discomfort was induced in 9 patients (pain group, PG) by pressure-controlled rectal distension (H. pylori status: 8 positive, 1 negative). Patients not presenting with abdominal pain to rectal distension (nonpain group, NPG) were all H. pylori negative (p < 0.001). L3 as an indicator of VH was reached at a lower pressure threshold in PG than in NPG or CG (p < 0.05). The perception was not different between NPG and CG (p > 0.05). CONCLUSIONS: The induction of typical abdominal discomfort in patients with IBS by the use of rectal barostat occurred predominantly in H. pylori infected patients and suggests that H. pylori infection may be involved in triggering VH in patients with IBS. Further studies in larger patient groups and after H. pylori eradication therapy are needed to confirm and extend this observation.     

艰难梭菌在肠易激综合征和炎症性肠病患者中的感染情况及与白细胞介素-8基因-251A/T多态性的关系研究

目的探讨艰难梭菌(C.difficile)在肠易激综合征(IBS)和炎症性肠病(IBD)患者中的感染情况及与白细胞介素8(IL-8)基因-251 A/T多态性的关系。方法研究选取经澄城县人民医院消化内科及肛肠科诊断为IBS、溃疡性结肠炎(UC)、克罗恩病(CD)的患者(分别为76例、90例、83例),同时选取90位健康志愿者作为对照组,比较C.difficile在各组中的感染情况,探讨C.difficile感染与基因位点多态性的关系。结果 UC组、CD组的感染率显著高于IBS组和对照组(P0.05),而IBS组与对照组的C.difficile感染率差异无统计学意义(P0.05),UC组与CD组的感染率差异亦无统计学意义(P0.05)。UC组血液中IL-8的浓度高于CD组、IBS组及对照组,而CD组的浓度高于IBS组和对照组,IBS组及对照组血液中IL-8浓度的差异无统计学意义(P0.05)。结论 C.difficile感染可使患者血液中IL-8浓度升高,IL-8基因-251 A/T多态性AA基因型是C.difficile感染的危险因素。     

The Incidence of Irritable Bowel Syndrome Among Community Subjects With Previous Acute Enteric Infection

The purpose of this study was to determine the incidence of postinfectious irritable bowel syndrome (IBS) among community subjects with positive stool studies. This was a prospective cohort study whereby all individuals with stool-positive acute enteric infection (AEI) were recruited from 3 health regions in Ontario, Canada. Each person completed questionnaires regarding preinfectious bowel habit and their bowel habit 3 months postinfection. Manning and Rome I criteria were used to diagnose irritable bowel syndrome. Two hundred thirty-one patients participated. Forty had preexisting IBS and were excluded. Of the remaining 191 patients, 7 developed irritable bowel syndrome, for an incidence of 3.7% (95% confidence interval: 1.0–6.3%). Fever during AEI was the only identifiable risk factor for developing postinfectious IBS (odds ratio, 11.96; P = .02). The incidence of postinfectious IBS in community subjects is 3.7%. Fever during the AEI may be an important risk factor for this condition.     

肠道感染与肠易激综合征

目的 探讨肠道急性感染与肠易激综合征（IBS）的关系。方法 对患病前无肠功能紊乱的295例痢疾／肠炎患者（235例为细菌性痢疾）及243例未曾患过痢疾／肠炎的配偶或兄弟姐妹（对照组）进行随访。检测了30例IBS患者及12例对照组末端回肠、直肠与乙状结肠交界处肠黏膜内白细胞介素（IL）－1α、IL－1β、IL－1ra的mRNA表达。结果 患过痢疾／肠炎者1－2年内66例（22．4％）有持续的肠功能紊乱,24例（占痢疾病人的10．2％）发展为IBS。对照组肠功能紊乱的患病率为7．4％,IBS的患病率为0．8％。其中痢疾／肠炎长者,发生肠功能紊乱的危险度高,8－＞15d的OR＝3．5－4．6。有痢疾／肠炎史的IBS患者末端回肠、直肠与乙状结肠交界处肠黏膜IL－1β mRNA的表达增高。结论 肠道感染可能通过免疫因素参与IBS的发病。     

The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome

OBJECTIVE: Irritable bowel syndrome (IBS) is associated with an exaggerated response to a variety of physiological and nonphysiological gastrointestinal stimuli. Many patients with IBS also have functional dyspepsia. Our aim was to examine the hypothesis that Helicobacter pylori (H. pylori) infection may predispose IBS patients to functional dyspepsia. METHODS: In 69 IBS patients, dyspeptic symptoms, H. pylori status, and sociodemographic and psychological variables (perceived stress, trait anxiety, and depression) were assessed. Sociodemographic and psychological variables were also evaluated in 52 control subjects. RESULTS: Mean scores for perceived stress (17.1 +/- 6.0 vs 14.9 +/- 6.0, p = 0.05), trait anxiety (45.6 +/- 9.1 vs 41.1 +/- 7.8, p = 0.004) and depression (9.9 +/- 8.4 vs 5.0 +/- 5.5, p = 0.0002) were higher in IBS patients than in controls. In all, 33 of the 69 patients (47.8%) had H. pylori infection, and this was associated with relevant symptoms of epigastric pain (odds ratio [OR] = 6.77, 95% confidence interval [CI] 1.89-24.3) and postprandial upper abdominal fullness (OR = 4.23, 95% CI 1.38-13.2). H. pylori infection and female gender were independent predictors of the presence of relevant dyspepsia (OR = 8.31, 95% CI 2.35-29.5 and 6.06, 95% CI 1.71-21.5, respectively). Symptom intensity was associated with the level of perceived stress (total relevant symptom number > or =3 vs <3, OR = 1.16 per point on a 40-point perceived stress scale, 95% CI 1.01-1.34). CONCLUSIONS: In IBS patients, the presence of dyspepsia is associated with H. pylori infection, female gender, and perceived stress.     

赛乐特联合匹维溴铵治疗肠易激综合征

目的 观察匹维溴铵、赛乐特对肠易激综合征的疗效。方法 98例随机分为两组,实验组(S组)58例,赛乐特20mg,1次/日,匹维溴铵薄膜包衣片50mg,每天3次;对照组(P组)40例;单用匹维溴铵50mg,每天3次,两组均每3天进行心理疏导1次,4周为1个疗程。结果 S组显效率58.62％,有效率37.93％,总有效率96.55％;P组显效率47.50％,有效率32.50％,总有效率80％(P<0.05)。结论 赛乐特,匹维溴铵联合治疗肠易激综合征较单用匹维溴铵疗效好。